| アイテムタイプ |
itemtype_ver1(1) |
| 公開日 |
2024-05-27 |
| タイトル |
|
|
タイトル |
Treatment escalation and de-escalation of de-novo metastatic castration-sensitive prostate cancer |
|
言語 |
en |
| 著者 |
Akamatsu, Shusuke
Naito, Yushi
Nagayama, Jun
Sano, Yuta
Inoue, Satoshi
Matsuo, Kazuna
Sano, Tomoyasu
Ishida, Shohei
Matsukawa, Yoshihisa
Kato, Masashi
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
|
言語 |
en |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
prostate cancer |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
metastasis |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
systemic therapy |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
local therapy |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
metastasis-directed therapy |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Androgen receptor signaling inhibitors combined with androgen deprivation therapy have become the standard of care for metastatic castration-sensitive prostate cancer (mCSPC), regardless of tumor volume or risk. However, survival of approximately one-third of these patients has not improved, necessitating further treatment escalation. On the other hand, for patients with oligometastatic mCSPC, there is an emerging role for local radiation therapy. Although data remain scarce, it is expected that treatment of both primary tumor as well as metastasis-directed therapy may improve survival outcomes. In these patients, systemic therapy may be de-escalated to intermittent therapy. However, precise risk stratification is necessary for risk-based treatment escalation or de-escalation. In addition to risk stratification based on clinical parameters, research has been conducted to incorporate genomic and/or transcriptomic data into risk stratification. In future, an integrated risk model is expected to precisely stratify patients and guide treatment strategies. Here, we first review the transition of the standard treatment for mCSPC over the last decade and further discuss the newest concept of escalating or de-escalating treatment using a multi-modal approach based on the currently available literature. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Nagoya University Graduate School of Medicine, School of Medicine |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプresource |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| ID登録 |
|
|
ID登録 |
10.18999/nagjms.86.2.169 |
|
ID登録タイプ |
JaLC |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/862.html |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0027-7622 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2186-3326 |
| 書誌情報 |
en : Nagoya Journal of Medical Science
巻 86,
号 2,
p. 169-180,
発行日 2024-05
|
02_Akamatsu.pdf (929 KB)
.png)
